Schrödinger takes a step for­ward with Al­phaFold in drug R&D, as biotech hits a pipeline 'in­flec­tion'

Schrödinger has work­shopped a fix for one of the biggest prob­lems with Al­phaFold-gen­er­at­ed pro­tein struc­ture pre­dic­tions, in what the com­pa­ny is de­scrib­ing as a no­table …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER